These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 32735884)

  • 1. CRISPR/Cas9 novel therapeutic road for the treatment of neurodegenerative diseases.
    Karimian A; Gorjizadeh N; Alemi F; Asemi Z; Azizian K; Soleimanpour J; Malakouti F; Targhazeh N; Majidinia M; Yousefi B
    Life Sci; 2020 Oct; 259():118165. PubMed ID: 32735884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular vesicle and CRISPR gene therapy: Current applications in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease.
    Akyuz E; Aslan FS; Gokce E; Ilmaz O; Topcu F; Kakac S
    Eur J Neurosci; 2024 Oct; 60(8):6057-6090. PubMed ID: 39297377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
    Karimian A; Azizian K; Parsian H; Rafieian S; Shafiei-Irannejad V; Kheyrollah M; Yousefi M; Majidinia M; Yousefi B
    J Cell Physiol; 2019 Aug; 234(8):12267-12277. PubMed ID: 30697727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Creating cell and animal models of human disease by genome editing using CRISPR/Cas9.
    Zarei A; Razban V; Hosseini SE; Tabei SMB
    J Gene Med; 2019 Apr; 21(4):e3082. PubMed ID: 30786106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing CRISPR/Cas9 technology in cardiovascular disease.
    Rezaei H; Khadempar S; Farahani N; Hosseingholi EZ; Hayat SMG; Sathyapalan T; Sahebkar AH
    Trends Cardiovasc Med; 2020 Feb; 30(2):93-101. PubMed ID: 30935726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of combined viral transduction and CRISPR/Cas9 gene editing in treating neurodegenerative diseases.
    Kuruvilla J; Sasmita AO; Ling APK
    Neurol Sci; 2018 Nov; 39(11):1827-1835. PubMed ID: 30076486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR Genome Editing Technology and its Application in Genetic Diseases: A Review.
    Khatibi S; Sahebkar A; Aghaee-Bakhtiari SH
    Curr Pharm Biotechnol; 2021; 22(4):468-479. PubMed ID: 32564746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in therapeutic CRISPR/Cas9 genome editing.
    Savić N; Schwank G
    Transl Res; 2016 Feb; 168():15-21. PubMed ID: 26470680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-Cas9 for treating hereditary diseases.
    Mani I
    Prog Mol Biol Transl Sci; 2021; 181():165-183. PubMed ID: 34127193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The application of CRISPR-Cas9 gene editing technology in viral infection diseases].
    Yin LJ; Hu SQ; Guo F
    Yi Chuan; 2015 May; 37(5):412-8. PubMed ID: 25998428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 System and its Research Progress in Gene Therapy.
    Liu W; Yang C; Liu Y; Jiang G
    Anticancer Agents Med Chem; 2019; 19(16):1912-1919. PubMed ID: 31633477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR-Cas9 for cancer therapy: Opportunities and challenges.
    Chen M; Mao A; Xu M; Weng Q; Mao J; Ji J
    Cancer Lett; 2019 Apr; 447():48-55. PubMed ID: 30684591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The application of genome editing in studying hearing loss.
    Zou B; Mittal R; Grati M; Lu Z; Shu Y; Tao Y; Feng Y; Xie D; Kong W; Yang S; Chen ZY; Liu X
    Hear Res; 2015 Sep; 327():102-8. PubMed ID: 25987504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal Models.
    Barazesh M; Mohammadi S; Bahrami Y; Mokarram P; Morowvat MH; Saidijam M; Karimipoor M; Kavousipour S; Vosoughi AR; Khanaki K
    Curr Gene Ther; 2021; 21(2):130-148. PubMed ID: 33319680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas9: A Preclinical and Clinical Perspective for the Treatment of Human Diseases.
    Sharma G; Sharma AR; Bhattacharya M; Lee SS; Chakraborty C
    Mol Ther; 2021 Feb; 29(2):571-586. PubMed ID: 33238136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the gene editing tool, CRISPR-Cas9, for treating neurodegenerative diseases.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Neurochem Int; 2018 Jan; 112():187-196. PubMed ID: 28732771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Broad Application of CRISPR Cas9 in Infectious, Inflammatory and Neurodegenerative Diseases.
    Pahan K
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):534-536. PubMed ID: 31782056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9 Mediated Therapeutic Approach in Huntington's Disease.
    Alkanli SS; Alkanli N; Ay A; Albeniz I
    Mol Neurobiol; 2023 Mar; 60(3):1486-1498. PubMed ID: 36482283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.